HEMISPHERx Expands European CFS Treatment Programs via Targeted Networks of Medical Centers

PHILADELPHIA (PROTEXT) - HEMISPHERx Biopharma, Inc. (Amex:HEB; HEBws) announced today the roll-out of a new pan-European,expanded access treatment utilizing its flagship product,Ampligen(R) being developed for the severe forms of CFS/ME. InDecember, 1998, the Company's subsidiary, Hemispherx Europe,filed a full marketing application with the European MedicalEvaluation Agency (EMEA) which is presently under review. Until today, the Company's cost recovery Ampligen treatmentprogram was only available in Belgium and Austria. Effectiveimmediately, in response to growing requests from physicians andpatients, the Company announced it would support expanded accesstreatment requests from pre-qualified medical centers andphysicians in France and Italy with similar programs in othermajor countries ramping up shortly. Ampligen is the onlypharmaceutical product under advanced clinical development forCFS/ME in both the European and North American markets. CFS/MEcan result in a severe chronic bedridden condition with loss ofmental faculties. To implement the program, the Company will establish a networkof clinical centers with comprehensive expertise in CFS, termedFatigue Approved Clinical Treatment Centers (FACT). FACT centers,modeled on successful AIDS treatment centers in the U.S. andelsewhere, will be centers of medical excellence combining stateof the art diagnostic programs with well-developed treatmentexpertise. The Company stated that the medical outcomes withAmpligen treatment were fully discussed at the September, 1999,2nd International CFS Conference in Brussels, Belgium, and thatthe new diagnostic procedures being developed by REDLaboratories, a collaborative partner of Hemispherx, would bepresented in a major international peer-reviewed medicalpublication within the next several weeks. Managing Director of the new enterprise will be Manuel Gea,formerly on the executive marketing staff of BoehringerIngelheim. The Company said Mr. Gea was already well recognizedin Europe as a 21st century medical communications strategist whoalready had a successful track record in creating effectivenetworks, including internet services, to bring together majorparts of the healthcare universe (doctors, insurers, healthcareworkers, patient groups, etc.) for achieving shared goals. Theinnovative network structure of the overall FACT organization -flexible, cost-controlled, and electronically interconnected -will make information transfer more efficient and effective whiledramatically reducing the large overhead historically associatedwith traditional pharmaceutical market development teams. Information contained in this news release other thanhistorical information, should be considered forward-looking andis subject to various risk factors and uncertainties. Forinstance, the strategies and operations of HEMISPHERx involverisks of competition, changing market conditions, changes in lawsand regulations affecting these industries and numerous otherfactors discussed in this release and in the Company's filingswith the Securities and Exchange Commission. Accordingly, actualresults may differ materially from those in any forward lookingstatements. ots Original Text Service: HEMISPHERx Biopharma,Inc. Internet: http://www.newsaktuell.de Contact: William A.Carter, M.D., CEO & Chairman of HEMISPHERx Biopharma, Inc., 215-988-0080; or William Jenks, Institutional Investors, 212-232-2222, or fax, 212-232-3232, for HEMISPHERx Biopharma, Inc.; orManuel Gea, gea.m.83m@centraliens.fr; or Harris Freedman,Investor Relations, 212-572-0763, fax, 212-572-0764, both forHEMISPHERx Biopharma, Inc. Web site: http://www.hemispherx.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT